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Abstract: Introduction: Performance of painful diagnostic and therapeutic procedures is common in emergency depart-
ment (ED), and procedural sedation and analgesia (PSA) is a fundamental skill for every emergency physician.
This study was aim to compare the efficacy of remifentanil with fentanyl/midazolam in painless reduction of an-
terior shoulder dislocation. Methods: In this randomized, double blind, clinical trial the procedural character-
istics, patients satisfaction as well as adverse events were compared between fentanyl/midazolam and remifen-
tanil for PSA of 18–64 years old patients, which were presented to ED following anterior shoulder dislocation.
Results: 96 cases were randomly allocated to two groups (86.5% male). There were no significant difference be-
tween groups regarding baseline characteristics. Remifentanil group had lower duration of procedure (2.5±1.6
versus 4.6±1.8 minutes, p < 0.001), higher pain reduction (53.7±13.3 versus 33.5±19.6, p < 0.001), lower failure
rate (1 (2.1%) versus 15 (31.3%), p < 0.001), higher satisfaction (p = 0.005). Adverse events were seen in 12 (25%)
patients in midazolam/fentanyl and 8 (16.7%) cases in remifentanil group (p = 0.122). Conclusion: It seems
that use of remifentanil resulted in lower procedural time, lower failure rate, and lower pain during procedure
as well as higher patient satisfaction in comparison with midazolam/fentanyl combination in anterior shoulder
dislocation.
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1. Introduction
P
erformance of painful diagnostic and therapeutic pro-
cedures is common in emergency department (ED),
and procedural sedation and analgesia (PSA) is a fun-
damental and required skill for every emergency physician
(1, 2). With the wide range of procedures and high patient
population, the ability to individualize PSA and maximize the
risk/benefit ratio for each unique situation is essential (3).
One of the common painful procedures in ED is reduction
of dislocated shoulder joints. The glenohumeral joint is the
most commonly dislocated major joint in the body. The an-
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nual incidence is 17 per 100,000, and two distinct age peaks
are recognized, the first in men 20 to 30 years of age and
the second in older women (4). Analgesia and muscle re-
laxation through procedural sedation are often used to facili-
tate reduction (5). Fentanyl combined with midazolam is fre-
quently used as a safe PSA agent in ED (3). However, caution
must be exercised when using benzodiazepines and opioids
together because the risk for hypoxia and apnea is signiïňĄ-
cantly greater than when either is used alone (6, 7). Remifen-
tanil is a relatively new synthetic opioid with a potency
comparable to fentanyl but an exceptionally short context-
sensitive half-life of only 3–5 minutes (8, 9). However, cur-
rently there are insufficient published studies to warrant its
routine use. Efficacy of remifentanil in combination with
other agents is supported by several clinical trials (10–14),
but few studies have described the use of remifentanil alone
during performing procedures (15–17). The aim of this ran-
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domized clinical trial was to compare the efficacy of a pure
analgesia-based sedation regimen with remifentanil with a
conventional regimen consisting of fentanyl/midazolam for
moderate sedation of patients with anterior shoulder dislo-
cation.
2. Materials and Methods
2.1. Study design and settings
This study was a prospective, randomized, single-center, par-
allel group clinical trial, comparing fentanyl/midazolam to
remifentanil alone for moderate sedation in patients aged
18–64 years with anterior shoulder dislocation, who were
presented to the ED of Imam Reza Hospital, Mashhad for
closed reduction. This study was approved by the Ethics
Committee of our institute (91/570419 November 4, 2012)
and registered in Iranian registry of clinical trials under the
number IRCT: 2013011312115N1. Informed consent was
obtained from all the selected patients after explaining the
study.
2.2. Participants
The studied subjects were selected using convenience sam-
pling among the patients presented to the ED of a university-
affiliated tertiary care medical center over a 9-month pe-
riod between February 2013 and October 2013, with anterior
shoulder dislocation and requiring closed reduction. Those
aged 18–64 years with physical condition I (healthy and nor-
mal patients without previous medical history) and II (pa-
tients with mild systemic disease with no functional limita-
tion) according to the classification of American Society of
Anesthesiologists (ASA) were enrolled. All subjects with his-
tory of allergy to benzodiazepines and narcotics; prolonged
use of opioids or alcohol; consumption of sedative or anal-
gesic drugs before presenting to ED; sleep obstructive apnea
syndrome; maxillofacial malformations with high probabil-
ity of airway maintenance failure; pregnant; anterior disloca-
tion requiring referral to orthopedic operating room; severe
trauma and unstable hemodynamics; advanced heart dis-
ease; kidney failure; pneumonia; uncontrolled seizures; and
finally patients not willing to participate in the study were ex-
cluded.
2.3. Intervention
Using convenience sampling 96 patients were randomized
and included in the intention-to-treat analysis, 48 in fen-
tanyl/midazolam group and 48 in remifentanil group. Alloca-
tion assignments were generated by an online random num-
ber generator from http://www.randomizer.org/ and
placed in sealed opaque envelopes to be opened in sequen-
tial order by research associates. Physicians (trained senior
emergency medicine residents) and patients were blinded to
the type of medication. The investigators doing the analy-
sis were not the same as those administering drugs and per-
forming the procedures.
On arrival to the intervention room, where the requirements
to protect the airway and prevent aspiration as well as the
suitable pulmonary ventilation facilities were predicted, in-
travenous access, supplementary oxygen via nasal cannula
(2 liter/min), routine pulse oximetry and cardiac monitoring
were established for all the patients. Remifentanil hydrochlo-
ride (lyophilized powder in sterile vials each containing 1 mg
of the compound) was reconstituted diluted with standard
diluent. The pharmacy at the institute supplied the fentanyl
and midazolam from commercial stock.
The patients in group 1 received remifentanil (1 µg /kg body
weight bolus intravenous administration at a concentration
of 50 µl/ml , and repeated additional titrated to effect doses
of 1 µg /kg administered every minute until the completion
of reduction), while those in group 2 received 1.5 µg /kg fen-
tanyl in combination with 0.1 mg /kg midazolam titrated to
effect doses intravenously.
It should be noted that in this study, the aim of giving the
drugs was to achieve moderate sedation or conscious seda-
tion (Ramsay Sedation score 3), which implied the following:
patients only responded to commands; airway intervention
was not necessary; spontaneous ventilation of the patients
was adequate; and the patients cardiovascular function was
maintained. The amount of drugs to give score 3 sedation,
was determined by an attending emergency medicine spe-
cialist and the patient was judged to be sedated adequately
to begin undergoing reduction by him.
After sedation, reduction of anterior shoulder was performed
by employing traction and counter traction method in both
groups. Our trained emergency medicine resident rated the
pain perceived by the patient before and during the proce-
dure using 100 mm visual analog scale (VAS).
Demographic data were gathered for all patients. The inci-
dence of adverse events was determined by a trained emer-
gency medicine resident and was marked in a checklist that
included the following: respiratory adverse events (the need
for supplemental oxygen, ventilation with a bag-mask, ma-
neuver practices for maintaining the airway open, insertion
of airway, respiratory stimulation, and respiratory depres-
sion with SpO2 < 92% at any time during intravenous ad-
ministration of the drug until hospital discharge), and non-
respiratory complications (dysphoria, vomiting, headache,
myoclonus, nausea, stiffness, rash, cough, bronchospasm,
laryngospasm, stridor, apnea, seizures, restlessness, agita-
tion, and aspiration). At the time of discharge, our trained
emergency medicine resident recorded patient satisfaction
rate using a Likert scale with four options of excellent, good,
average, and poor.
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2.4. Study end-points
The primary end-points were pain reduction, procedure
time, patient satisfaction, and incidence of respiratory
adverse events. Secondary end-points included non-
respiratory adverse events.
2.5. Definitions
A successful reduction was determined clinically by the pres-
ence of a palpable clunk, decrease in pain, and improvement
in the range of motion.
Procedure time was defined as time from start of traction
to completion of reduction. The timing was measured and
recorded using a stopwatch.
2.6. Data Analysis
IBM SPSS statistics 21 was used for statistical analyses. Cat-
egorical variables were reported as number and percentage
and continuous ones as mean ± standard deviation. Chi-
square and Fisher exact tests were used for comparing cat-
egorical variables and t-test for comparing mean between
groups. P value < 0.05 was considered statistically signifi-
cant.
3. Results
48 cases received remifentanil and 48 received a combina-
tion of fentanyl and midazolam (86.5% male). The mean age
of remifentanil patients was 39.7 ± 10.3 years compared to
39.8±9.9 years for fentanyl and midazolam group (p = 0.952).
In remifentanil group 41 (85.4%) and in fentanyl and mida-
zolam group 42 (87.5%) cases were male (p = 0.5). The sub-
jects in both groups were stable regarding hemodynamic sta-
tus. The mean pain score at baseline was 70.3±10.8 mm for
fentanyl and midazolam and 76.6±11.9 mm for remifentanil
group (p = 0.008). Since the minimum clinically significant
difference of pain score was considered 30 mm for this study,
the baseline difference of pain severity between two groups
was not clinically significant. Table 1 compares the 2 groups
regarding procedure characteristics and observed complica-
tions. Respiratory adverse event was not experienced in any
of the groups. Non-respiratory adverse events were seen in
12 (25%) patients in midazolam/fentanyl and 8 (16.7%) cases
in remifentanil group (p = 0.122).
4. Discussion
When choosing a strategy for PSA, it is important to consider
the type of procedure being performed (painful or not), the
length of the procedure, specific procedural requirements
(anxiolysis vs. immobility), and whether sedation needs to
be prolonged. A risk-benefit analysis should be conducted
before performing PSA and the benefits of reducing anxiety
and pain versus the risk of respiratory depression and airway
disorders should be measured.
The results of the present study demonstrated a significantly
lower duration of procedure and lower failure rate in patients
that were sedated using remifentanil. On the other hand, the
mean pain reduction was significantly higher in remifentanil
group. Two groups had the same condition regarding respira-
tory and non-respiratory adverse events. The level of patient
satisfaction was significantly higher in remifentanil group.
Rai et al. studied remifentanil versus propofol for awake
fiberoptic intubation and reported signifcantly shorter en-
doscopy and intubation times for remifentanil group (15).
Dunn et al. demonstrated that propofol and remifentanil
provide excellent sedation and analgesia for the reduction
of anterior glenohumeral dislocation (10, 11). In Phillips et
al. case series an initial bolus dosage of 0.5–3 mcg /kg in-
travenous remifentanil with subsequent 0.25–1 mcg /kg bo-
luses resulted in mean pain severity of 1.1, mean procedure
time of 4 minutes and 17% respiratory complications requir-
ing temporary intervention during procedure (16).
The lower mean pain severity during the procedure with
remifentanil (9.4 ± 8.5 mm vs. 26.1 ± 20.2 mm) revealed
greater effectiveness and potency of this drug. This finding
was similar to Dunn et al., Phillips et al., Swann et al., Sac-
chetti et al., and Cok OY et al. findings (10, 12, 13, 16, 17).
Some non-respiratory adverse events have been reported us-
ing combination of midazolam/fentanyl (18). Application of
remifentanil in combination with midazolam for perform-
ing painful procedures in children resulted in high and un-
acceptable rate of hypoxemia (14). The incidence of respira-
tory and non-respiratory adverse events was similar in both
groups of the present study.
In this study, significantly higher patient satisfaction was
reported for patients sedated with remifentanil, which was
compatible with findings of Dunn et al. (10).
In the present study, for eliminating further confounding fac-
tors, the same technique of reduction was performed for all
patients in both groups. The study revealed that remifentanil
works effectively in PSA of patients with anterior shoulder
dislocation without addition of any sedative agents. Since
only adults between the ages of 21 and 64 years were stud-
ied, our findings cannot be extrapolated to children and the
elderly.
5. Conclusion
It seems that use of remifentanil resulted in lower procedu-
ral time, lower failure rate, and lower pain during procedure
as well as higher patient satisfaction in comparison with mi-
dazolam/fentanyl combination for procedural sedation and
analgesia in anterior shoulder dislocation. The 2 groups had
the same condition regarding respiratory and non-espiratory
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Table 1: Comparison of the 2 studied groups regarding procedure characteristics and observed complications
Variable Fentanyl + Midazolam Remifentanil P value
Mean procedure time (minute) 4.6±1.8 2.5±1.6 < 0.001
Pain severity during procedure# 36.8±22.9 22.9±9.9 < 0.001
Mean pain reduction 33.5±19.6 53.7±13.3 < 0.001
Failure rate 15 (31.3) 1 (2.1) < 0.001
Non-respiratory adverse events
Vomiting 2 (4.2) 0 (0) 0.247
Nausea 5 (10.4) 1 (2.1) 0.102
Itching 2 (4.2) 5 (10.4) 0.218
Cough 2 (4.2) 1 (2.1) 0.5
Agitation 1 (1.2) 0 (0) 0.5
Dysphoria 4 (8.3) 2 (4.2) 0.339
Total 12 (25) 8 (16.7) 0.122
Patient satisfaction
Excellent 32 (66.7) 43 (89.6) < 0.005
Good 16 (33.3) 5 (10.4)
Values are presented in mean ± standard deviation or number (%), pain severity was measured based on visual analogue scale (mil-
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